Introduction to Survival Analysis

David M. Rocke

May 9, 2017

Time to Event Data

- Survival Analysis is a term for analyzing time-to-event data.
- This is used in clinical trials, where the event is often death or recurrence of disease.
- It is used in engineering reliability analysis, where the event is failure of a device or system.
- It is used in insurance, particularly life insurance, where the event is death.

Time to Event Data

- The distribution of 'failure' times is asymmetric and can be long-tailed.
- The base distribution is not normal, but exponential.
- There are usually *censored* observations, which are ones in which the failure time is not observed.

Time to Event Data

- Usually, these are *right-censored*, meaning that we know that the event occurred after some known time t, but we don't know the actual event time, as when a patient is still alive at the end of the study.
- Observations can also be *left-censored*, meaning we know the event has already happened at time t, or *interval-censored*, meaning that we only know that the event happened between times t_1 and t_2.
- Analysis is difficult if censoring is associated with treatment.

Right Censoring

- Patients are in a clinical trial for cancer, some on a new treatment and some on standard of care.
- Some patients in each group have died by the end of the study. We know the survival time (say from diagnosis).
- Patients still alive at the end of the study are right censored.
- Patients who are lost to follow-up or withdraw from the study may be right-censored.

Left and Interval Censoring

- An individual tests positive for HIV.
- If the event is infection with HIV, then we only know that it has occurred before the testing time t, so this is left censored.
- If an individual has a negative HIV test at time t_1 and a positive HIV test at time t_2, then the infection event is interval censored.

Basic Quantities and Models

The probability density function $f(x)$ is defined as with any continuous distribution. For any short interval of time, it can be thought of as the chance that the event will occur in that short interval. The cumulative distribution function is

$$F(x) = \Pr(X \leq x) = \int_0^x f(x)dx$$

For survival data, a more relevant quantity is the *survival function*

$$S(x) = 1 - F(x) = \Pr(X > x) = \int_x^\infty f(x)dx$$

The Hazard Function

Another important function is the *hazard function*, which is the probability that the event will occur in the next very short interval, given that it has not occurred yet.

$$
\begin{aligned}
h(x) &= \lim_{\Delta x \to 0} \frac{\Pr[x \leq X < x + \Delta x | X \geq x]}{\Delta x} \\
&= f(x)/S(x) \\
f(x) &= -\frac{dS(x)}{dx} \\
h(x) &= -\frac{d \ln(S(x))}{dx}
\end{aligned}
$$

Cumulative Hazard

$$h(x) = -\frac{d \ln(S(x))}{dx}$$

The cumulative hazard function is

$$H(x) = \int_0^x h(x)dx = -\ln(S(x))$$

This function is easier to estimate than the hazard function, and we can then approximate the hazard function by the approximate derivative of the cumulative hazard.


Daily Hazard Rates in 2004 for US Females
First Day
Rest of First Week
Rest of First month
Daily Hazard Rate
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0
20
40
60
80
100
Age


Daily Hazard Rates in 2004 for US Males and Females 1−40
Daily Hazard Rate
1e−06
2e−06
3e−06
4e−06
5e−06
6e−06
Males
Females
0
10
20
30
40
Age


Survival Curve in 2004 for US Females
Survival
1.0
0.8
0.6
0.4
0.2
0.0
0
20
40
60
80
100
Age

Exponential Distribution

- The exponential distribution is the base distribution for survival analysis.
- The distribution has a constant hazard λ
- The mean survival time is λ^{-1}

$$
\begin{aligned}
f(x) &= \lambda e^{-\lambda x} \\
\ln(f(x)) &= \ln\lambda - \lambda x \\
F(x) &= 1 - e^{-\lambda x} \\
S(X) &= e^{-\lambda x} \\
\ln(S(x)) &= -\lambda x \\
h(x) &= -\frac{d}{dx}\ln(S(x)) \\
&= -\frac{d}{dx}(-\lambda x) \\
&= \lambda
\end{aligned}
$$

Estimation of λ

Suppose we have m exponential survival times of $t_1, t_2, \ldots, t_m$ and k right-censored values at $u_1, u_2, \ldots, u_k$. The log-likelihood of an observed survival time t_i is $\ln \lambda - \lambda t_i$ and the likelihood of a censored value is the probability of that outcome (survival greater than u_j) so the log-likelihood is $-\lambda u_j$. Let $T = \sum t_i$ and $U = \sum u_j$. Then the log likelihood is

$$m \ln \lambda - (T + U)\lambda$$

$$m \ln \lambda - (T + U)\lambda$$

is maximized when the derivative is 0, that is when

$$\begin{aligned} 0 &= m/\lambda - (T + U) \\ \lambda &= m/(T + U) \\ 1/\lambda &= (T + U)/m \end{aligned}$$

It can be show that the variance of $\hat{\lambda}$ is asymptotically λ^2/m, depending only on the number of uncensored observations. This is generally true.

Mean Residual Life

The mean lifetime with a survival distribution $f(x)$ is

$$\int_0^\infty xf(x)dx$$

For the exponential distribution we know that the mean is λ^{-1} The mean residual life after survival to time x is

$$\begin{aligned} mrl(x) &= \int_x^\infty (u-x)f(u)du / \int_x^\infty f(u)du \\ &= \int_x^\infty S(u)du/S(x) \end{aligned}$$

For the exponential, the mean residual life is also λ^{-1}

Other Parametric Survival Distributions

- Any density on $[0, \infty)$ can be a survival distribution, but the most useful one are all skew right.
- The commonest generalization of the exponential is the Weibull.
- Other common choices are the gamma, log-normal, log-logistic, Gompertz, inverse Gaussian, and Pareto.
- Most of what we do going forward is non-parametric, but sometimes these parametric distributions provide a useful approach.

Weibull Distribution

$$\begin{aligned} f(x) &= \alpha\lambda x^{\alpha-1} e^{-\lambda x^{\alpha}} \\ h(x) &= \alpha\lambda x^{\alpha-1} \\ S(x) &= e^{-\lambda x^{\alpha}} \\ E(X) &= \Gamma(1+1/\alpha)/\lambda^{1/\alpha} \end{aligned}$$

When $\alpha = 1$ this is the exponential. When $\alpha > 1$ the hazard is increasing and when $\alpha < 1$ the hazard is decreasing. This provides more flexibility than the exponential.

Nonparametric Survival Analysis

- Mostly, we work without a parametric model.
- The first task is to estimate a survival function from data listing survival times, and censoring times for censored data.
- For example one patient may have relapsed at 10 months. Another might have been followed for 32 months without a relapse having occurred (censored).
- The minimum information we need for each patient is a time and a censoring variable which is 1 if the event occurred at the indicated time and 0 if this is a censoring time.

KM drug6mp Data

Clinical trial in 1963 for 6-MP treatment vs. placebo for Acute Leukemia in 42 children. Pairs of children matched by remission status (1 = partial or 2 = complete) and randomized to 6-MP or placebo. Followed until relapse or end of study. All of the placebo group relapsed, but some of the 6-MP group were censored.

```
> library(KMsurv)
> data(drug6mp)
> drug6mp
   pair remstat t1 t2 relapse
1     1       1  1 10       1
2     2       2 22  7       1
3     3       2  3 32       0
```

KM drug6mp Data

```
drug6mp data

Description

The drug6mp data frame has 21 rows and 5 columns.

Format

This data frame contains the following columns:

pair          pair number
remstat       Remission status at randomization (1=partial, 2=complete)
t1            Time to relapse for placebo patients, months
t2            Time to relapse for 6-MP patients, months
relapse       Relapse indicator (0=censored, 1=relapse) for 6-MP patients
```

Descriptive Statistics

- The average time in each group is not useful. Some of the 6-MP patients have not relapsed at the time recorded, while all of the placebo patients have relapsed.
- The median time is not really useful either because so many of the 6-MP patients have not relapsed (12/21).
- Both are biased down in the 6-MP group.

Descriptive Statistics

- We can compute the average hazard rate, which is the estimate of the exponential parameter: number of relapses divided by the sum of the times.
- For the placebo, that is just the reciprocal of the mean time $= 1/8.667 = 0.115$.
- For the 6-MP group this is $9/359 = 0.025$
- The estimated average hazard in the placebo group is 4.6 times as large.

The Kaplan-Meier Product Limit Estimator

- The survival function for the placebo patients is easy to compute. For any time t in months, $S(t)$ is the fraction of patients with times greater than t.
- For the 6-MP patients, we cannot ignore the censored data because we know that the time to relapse is greater than the censoring time.
- The procedure we usually use is the Kaplan-Meier product-limit estimator of the survival function.

- The Kaplan-Meir estimator is a step function (like the empirical cdf), which changes value only at the event times, not at the censoring times.
- At each event time t, we compute the at-risk group size Y, which is all those observations whose event time or censoring time is at least t.
- If d of the observations have an event time (not a censoring time) of t, then the group of survivors immediately following time t is reduced by the fraction

$$\frac{Y-d}{Y} = 1 - \frac{d}{Y}$$

If the event times are t_i with events per time of d_i $(1 \leq i \leq k)$, then

$$\hat{S}(t) = \prod_{t_i < t} [1 - d_i / Y_i]$$

where Y_i is the set of observations whose time (event or censored) is $\geq t_i$, the group at risk at time t_i.

If there are no censored data, and there are n data points, then just after (say) the third event time

$$\begin{aligned}
\hat{S}(t) &= \prod_{t_i<t}[1 - d_i/Y_i] \\
&= [\frac{n-d_1}{n}][\frac{n-d_1-d_2}{n-d_1}][\frac{n-d_1-d_2-d_3}{n-d_1-d_2}] \\
&= \frac{n-d_1-d_2-d_3}{n}
\end{aligned}$$

the usual empirical cdf estimate.

```
require(KMsurv)
data(drug6mp)
plot(survfit(Surv(drug6mp$t2,drug6mp$relapse)~1))
title("Kaplan-Meier Survival Curve for 6-MP Patients")

time12 <- c(drug6mp$t1,drug6mp$t2)
cens12 <- c(rep(1,21),drug6mp$relapse)
treat12 <- rep(1:2,each=21)
pairs12 <- rep(1:21,2)

plot(survfit(Surv(time12,cens12)~treat12),col=1:2)
title("Kaplan-Meier Survival Curve for 6-MP and Placebo Patients")

plot(survfit(Surv(time12,cens12)~treat12),conf.int=T,col=1:2)
title("Kaplan-Meier Survival Curve for 6-MP and Placebo Patients")
```

Time	At Risk	Relapses	Censored	KM Factor	KM Curve
6	21	3	1	0.857	0.857
7	17	1	0	0.941	0.807
9	16	0	1	1	0.807
10	15	1	1	0.933	0.753
11	13	0	1	1	0.753
13	12	1	0	0.917	0.690
16	11	1	0	0.909	0.627
17	10	0	1	1	0.627
19	9	0	1	1	0.627
20	8	0	1	1	0.627
22	7	1	0	0.857	0.538
23	6	1	0	0.833	0.448
25	5	0	1	1	0.448
32	4	0	2	1	0.448
34	2	0	1	1	0.448
35	1	0	1	1	0.448

At time 6 months, there are 21 patients at risk. At $t = 6$ there are 3 relapses and 1 censored observations. The Kaplan-Meier factor is $(21 - 3)/21 = 0.857$. The number at risk for the next time $(t = 7)$ is $21 - 3 - 1 = 17$.

At time 7 months, there are 17 patients at risk. At $t = 7$ there is 1 relapse and 0 censored observations. The Kaplan-Meier factor is $(17 - 1)/17 = 0.941$. The Kaplan Meier estimate is $0.857 \times 0.941 = 0.807$. The number at risk for the next time $(t = 9)$ is $17 - 1 = 16$.

```
time12 <- c(drug6mp$t1,drug6mp$t2)
cens12 <- c(rep(1,21),drug6mp$relapse)
treat12 <- rep(1:2,each=21)
pairs12 <- rep(1:21,2)

print(survdiff(Surv(time12,cens12)~treat12))

           N Observed Expected (O-E)^2/E (O-E)^2/V
treat12=1 21       21     10.7      9.77      16.8
treat12=2 21        9     19.3      5.46      16.8

 Chisq= 16.8  on 1 degrees of freedom, p= 4.17e-05

print(survdiff(Surv(time12,cens12)~treat12+strata(pairs12)))

           N Observed Expected (O-E)^2/E (O-E)^2/V
treat12=1 21       21     13.5      4.17      10.7
treat12=2 21        9     16.5      3.41      10.7

 Chisq= 10.7  on 1 degrees of freedom, p= 0.00106
```


Kaplan−Meier Survival Curve for 6−MP Patients
1.0
0.8
0.6
0.4
0.2
0.0
0
5
10
15
20
25
30
35


Kaplan−Meier Survival Curve for 6−MP and Placebo Patients
1.0
0.8
0.6
0.4
0.2
0.0
0
5
10
15
20
25
30
35


Kaplan−Meier Survival Curve for 6−MP and Placebo Patients
1.0
0.8
0.6
0.4
0.2
0.0
0
5
10
15
20
25
30
35

Package Survival

```
Surv

Create a survival object, usually used as a response variable in a model formula.

Usage

Surv(time, event)

Arguments

time   for right censored data, this is the follow up time.

event   The status indicator, normally 0=alive, 1=dead.
        Also TRUE/FALSE (TRUE = death) or 1/2 (2=death).
        The event indicator can be omitted,
          in which case all subjects are assumed to have an event.
-----
Surv(drug6mp$t2,drug6mp$relapse)
```

Package Survival

```
survfit

This function creates survival curves from either a formula
(e.g. the Kaplan-Meier), a previously fitted Cox model,
or a previously fitted accelerated failure time model.

Usage

survfit(formula, ...)

Arguments

formula    either a formula or a previously fitted model
-----
plot(survfit(Surv(drug6mp$t2,drug6mp$relapse)~1))
plot(survfit(Surv(time12,cens12)~treat12))
```

Package Survival

```
survdiff

Tests if there is a difference between two or more survival curves.

Usage

survdiff(formula, data, subset, na.action, rho=0)

Arguments

formula     a formula expression as for other survival models,
            of the form Surv(time, status) ~ predictors.
            A strata term may be used to produce a stratified test.

rho         Type of test. Default is the Mantel-Haenszel test.
-------
print(survdiff(Surv(time12,cens12)~treat12))
print(survdiff(Surv(time12,cens12)~treat12+strata(pairs12)))
```